LV-009

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameLV-009
Drug Alias NameLV009LV-009
ClassificationCell and gene therapy > Gene therapy > mRNACell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapy +[4] 
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPersongen Anke Cell Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital With Nanjing Medical UniversityPersongen Biotherapeutics (Suzhou) Co Ltd
Inactive CompaniesPersongen Anke Cell Technology Co Ltd
Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A